Trade

with

Supernus Pharmaceuticals Inc
(NASDAQ: SUPN)
AdChoices
7.79
-0.09
-1.14%
After Hours :
7.79
0.00
0.00%

Open

7.87

Previous Close

7.88

Volume (Avg)

186.72k (424.87k)

Day's Range

7.74-8.04

52Wk Range

5.84-11.47

Market Cap.

334.36M

Dividend Rate ( Yield )

-

Beta

1.56

Shares Outstanding

42.92M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 12.02M

    • Net Income

    • -92.27M

    • Market Cap.

    • 334.36M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -116.88

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.56

    • Forward P/E

    • -

    • Price/Sales

    • 5.76

    • Price/Book Value

    • 10.02

    • Price/Cash flow

    • -5.95

      • EBITDA

      • -83.68M

      • Return on Capital %

      • -52.04

      • Return on Equity %

      • -169.92

      • Return on Assets %

      • -52.04

      • Book Value/Share

      • 0.78

      • Shares Outstanding

      • 42.92M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 10,460.50

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • 6.22

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 93.53

            • 64.72

            • Pre-Tax Margin

            • -116.88

            • 13.77

            • Net Profit Margin

            • -116.88

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • 98.20

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • 397.20

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.86

              • 0.33

              • Current Ratio

              • 3.75

              • 1.52

              • Quick Ratio

              • 3.06

              • 0.87

              • Interest Coverage

              • -6.89

              • 6.77

              • Leverage Ratio

              • 2.82

              • 1.91

              • Book Value/Share

              • 0.78

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -5.16

                • 63.29

                • P/E Ratio 5-Year High

                • -10.55

                • 237.47

                • P/E Ratio 5-Year Low

                • -2.72

                • 19.71

                • Price/Sales Ratio

                • 6.03

                • 3.53

                • Price/Book Value

                • 10.49

                • 3.31

                • Price/Cash Flow Ratio

                • -5.95

                • 21.23

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -169.92

                        (-)

                      • 7.86

                        (9.58)

                      • Return on Assets %

                        (5-Year Average)

                      • -52.04

                        (-24.80)

                      • 4.14

                        (5.54)

                      • Return on Capital %

                        (5-Year Average)

                      • -65.44

                        (-)

                      • 5.59

                        (7.66)

                      • Income/Employee

                      • -

                      • 27.79k

                      • Inventory Turnover

                      • 0.45

                      • 1.80

                      • Asset Turnover

                      • 0.45

                      • 0.38

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -61.92M
                      Operating Margin
                      -515.18
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -5.95
                      Ownership

                      Institutional Ownership

                      -

                      Top 10 Institutions

                      101.62%

                      Mutual Fund Ownership

                      22.10%

                      Float

                      60.17%

                      5% / Insider Ownership

                      1.56%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • T. Rowe Price Health Sciences Fund

                      •  

                        1,549,200

                      • -27.72

                      • 3.68

                      • T. Rowe Price New Horizons Fund

                      •  

                        1,218,900

                      • -2.10

                      • 2.89

                      • Columbia Small Cap Core Fund

                      •  

                        688,656

                      • 0.00

                      • 1.60

                      • Worldwide Healthcare

                      •  

                        580,000

                      • 0.00

                      • 1.38

                      • iShares Nasdaq Biotechnology

                      •  

                        573,733

                      • 3.08

                      • 1.21

                      • iShares Russell 2000 (AU)

                      •  

                        466,933

                      • 1.67

                      • 0.99

                      • Vanguard Total Stock Mkt Idx

                      •  

                        465,212

                      • 0.00

                      • 1.08

                      • Columbia Small Cap Value Fund I

                      •  

                        380,836

                      • 0.00

                      • 0.89

                      • Mutual of America Small Cap Growth

                      •  

                        355,272

                      • -19.57

                      • 0.84

                      • Mutual of America Small Cap Value

                      •  

                        325,058

                      • -26.28

                      • 0.77

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • NEA Management Company, LLC

                      •  

                        10,650,000

                      • 0.00%

                      • 25.04

                      • Abingworth LLP

                      •  

                        3,600,000

                      • 0.00%

                      • 8.53

                      • Abingworth Management Ltd

                      •  

                        3,277,869

                      • -8.95%

                      • 7.64

                      • T. Rowe Price Associates, Inc.

                      •  

                        2,815,530

                      • -6.20%

                      • 6.56

                      • Discovery Group I, Llc

                      •  

                        2,785,153

                      • +21.01%

                      • 6.49

                      • Ardsley Advisory Partners

                      •  

                        1,765,000

                      • +11.01%

                      • 4.19

                      • Columbia Mangmt Investment Advisers, LLC

                      •  

                        1,732,581

                      • -6.72%

                      • 4.11

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Drug Manufacturers – Specific & Generic

                      Type

                      Distressed

                      Style

                      -

                      Supernus Pharmaceuticals Inc., was incorporated in Delaware on March 30, 2005. It is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, includin...moreg neurological and psychiatric disorders. The Company markets two epilepsy products, Oxtellar XR and Trokendi XR, and has several proprietary product candidates in clinical development that address the attention deficit hyperactivity disorder market. The Company has a broad portfolio of drug development technologies consisting of six platforms that include the following: Microtrol, Solutrol (matrix delivery platform) and EnSoTrol. In addition to Oxtellar XR and Trokendi XR, the Company’s proprietary technologies have been used in the following approved products: Carbatro...morel, Adderall XR, and Intuniv, marketed by Shire; Equetro, marketed by Validus Pharmaceuticals Inc.; Sanctura XR, marketed by Allergan, Inc.; Oracea, marketed by Galderma Laboratories, L.P.; and Orenitram. Oxtellar XR and Trokendi XR are novel extended release formulations of two well known and approved AEDs, oxcarbazepine and topiramate. The Company’s psychiatry portfolio includes three product candidates for the treatment of impulsive aggression in patients with ADHD, ADHD or its coexisting conditions and one product candidate for depression, each of which is designed to bring important advancements in therapy. In addition to regulations in the United States, the Company will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of the product candidates to the extent company choose to clinically evaluate or sell any products outside of the United States.lessless

                      Key People

                      Jack Khattar

                      CEO/Director/President/Secretary

                      Dr. M. James Barrett,PhD

                      Chairman of the Board/Director

                      Gregory S. Patrick

                      CFO/Chief Accounting Officer/Vice President

                      Dr. Stefan K.F. Schwabe, M.D., Ph.D.

                      Chief Medical Officer/Executive VP, Divisional

                      Jones W. Bryan

                      Vice President, Divisional

                      • Supernus Pharmaceuticals Inc

                      • 1550 East Gude Drive

                      • Rockville, MD 20850

                      • USA.Map

                      • Phone: +1 301 838-2500

                      • Fax: -

                      • supernus.com

                      Incorporated

                      2005

                      Employees

                      235

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: